Paper Review Records
全部论文审稿周期
5 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
110
天
Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer
作者
Lijie Zhang; Jingwen Wang; Juefeng Wan; Yan Wang; Hui Zhang; Yaqi Wang; Fan Xia; Lijun Shen; Zhen Zhang展开收起
作者单位
1. Department of Radiation Oncology, 89667Fudan University Shanghai Cancer Center, Shanghai, China; 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; 3. Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China; 4. Shanghai Key Laboratory of Radiation Oncology, Shanghai, China; 5. Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China展开收起
174
天
Chemotherapy relative dose intensity and survival outcomes in pediatric and adolescent locoregionally advanced nasopharyngeal carcinoma: A retrospective cohort study
作者
Zi-Xuan Chen; Ye-Hao Zou; Rui-Ling Xie; Ling-Ling Zhang; Chao Lin; Rui Sun展开收起
作者单位
1. Department of Nasopharyngeal Carcinoma, 71067Sun Yat-sen University Cancer Center, Guangzhou, China; 2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 71067Sun Yat-sen University Cancer Center, Guangzhou, China; 3. Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 71067Sun Yat-sen University Cancer Center, Guangzhou, China; 4. Department of Radiation Oncology, 117890FuJian Medical University Union Hospital, Fuzhou City, Fujian Province, China展开收起
161
天
Risk stratification and boost dose optimization for locoregionally advanced nasopharyngeal carcinoma with residual lesions based on clinical stage and post-radiotherapy EBV DNA
作者
Xinyi Hong; Yi Li; Chaoying Lin; Jianxian Chen; Haosheng Zhang; Weijian Liu; Lanxin Lin; Zongying Qian; Sihan Lin; Yuhui Pan; Sufang Qiu展开收起
作者单位
1. 74551Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China; 2. Sanya People’s Hospital, West China (Sanya) Hospital, Sichuan University, Sanya, China; 3. NHC Key Laboratory of Cancer and Metabolism, 66552Fujian Cancer Hospital, Fuzhou, Fujian, China展开收起
140
天
Historical evaluation of clinical outcomes and safety following isolated limb perfusion for unresectable melanoma: Real-world data from the Mannheim Cancer Center
作者
Danai-Dionysia Kanatoula; Sebastian A. Wohlfeil; Corinne Hübers; Janna Eith; Jens Jakob; Peter Hohenberger; Jochen Utikal展开收起
作者单位
1. Department of Dermatology, Venereology, and Allergology, 36642University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, Mannheim, Germany; 2. Skin Cancer Unit, 28333German Cancer Research Center (DKFZ), Heidelberg, Germany; 3. DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; 4. Department of Surgery, Medical Faculty Mannheim, Sarcoma Unit, 36642University Medical Center Mannheim, Heidelberg University, Mannheim, Germany展开收起
154
天
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study
作者
Davide Bimbatti; Cecilia Nasso; Domiziana Aspden; Sebastiano Buti; Ludovica Antonj; Alessio Signori; Elena Verzoni; Cristian Lolli; Marilena Di Napoli; Martina Fanelli; Miriam De Lucia; Cristina Masini; Giandomenico Roviello; Daniela Arduini; Roberto Filippi; Alessia Mennitto; Mariella Sorarù; Giovanni Bozza; Luigi Formisano; Carlo Messina; Lucia Bonomi; Annalisa Guida; Emanuela Fantinel; Sarah Scagliarini; Maria Giuseppa Vitale; Silvia Chiellino; Brigida Anna Maiorano; Filippo Maria Deppieri; Paolo Andrea Zucali; Alessia Cavo; Claudia Caserta; Francesca La Russa; Vincenza Conteduca; Francesca Maines; Silvia Zai; Francesco Pierantoni; Massimiliano Icardi; Pasquale Rescigno; Fabrizio Di Costanzo; Giuseppe Luigi Banna; Sara Elena Rebuzzi展开收起
作者单位
1. Oncology 1 Unit, Istituto Oncologico Veneto IOV–IRCCS, Padua, Italy; 2. Medical Oncology, Ospedale Santa Corona, Pietra Ligure, Italy; 3. University of Turin, A.O.U. Città della Salute e della Scienza di Torino, Ospedale Molinette, Turin, Italy; 4. Medical Oncology Unit, University Hospital of Parma, Parma, Italy; 5. Medicine and Surgery Department, University of Parma, Parma, Italy; 6. Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 7. Department of Health Sciences, Section of Biostatistics, University of Genova, Via Pastore 1, Genoa 16132, Italy; 8. IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, Genoa 16132, Italy; 9. Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 10. Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy; 11. Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy; 12. Department of Medical Oncology, Department of Medicine (DAME), University of Udine, Udine, Italy; 13. Unit of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy; 14. Medical Oncology. Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; 15. Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Florence, Italy; 16. Università Cattolica del Sacro Cuore, Facoltà di Medicina e Chirurgia, Rome, Italy; 17. Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 18. Medical Oncology 1U, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; 19. Department of Medical Oncology, Azienda Ospedaliera Universitaria “Maggiore Della Carità,” Novara, Italy; 20. U.O. Oncologia, Ospedale di Camposampiero, Camposampiero, Italy; 21. Medical Oncology IRCSS CROB, Rionero in Vulture, Italy; 22. Department of Clinical Medicine and Surgery at University of Naples Federico II, Naples, Italy; 23. Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy; 24. Medical Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; 25. Medical Oncology Unit, Santa Maria Hospital, Terni, Italy; 26. Department of Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Verona, Italy; 27. Deparment of Medical Oncology, AORN “A. Cardarelli,” Naples, Italy; 28. Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; 29. Medical Oncology Unit, IRCCS Policlinico San Matteo, Pavia, Italy; 30. Department of Medical Oncology, IRRCS San Raffaele Hospital, Milan, Italy; 31. Medical Oncology Unit, AULSS 3 Serenissima, Mestre-Venice, Italy; 32. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 33. Department of Oncology, IRCCS, Humanitas Clinical and Research Center, Rozzano, Milano, Italy; 34. Oncology Unit, ASL3-Villa Scassi Hospital, Genoa, Italy; 35. Oncology Unit, Santa Maria della Misericordia Hospital Perugia, Italy; 36. Department of Oncology, Ospedale San Bortolo, Vicenza, Italy; 37. Unit of Medical Oncology and Biomolecular Therapy and CREATE Center for Research and Innovation in Medicine, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy; 38. Medical Oncology, Santa Chiara Hospital, Trento, Italy; 39. Medical Oncology Unit, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; 40. Oncology 3 Unit, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy; 41. Medical Oncology Unit 2, Ospedale Molinette, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; 42. Department of Oncology, Candiolo Cancer Institute FPO-IRCCS, Turin, Italy; 43. Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK; 44. Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK; 45. Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天